Showing 25 to 36 of 79 results
25 Years of Cancer Research at CIC: Extending Lives and Transforming Treatments
The Centro de Investigación del Cáncer (CIC) in Salamanca, Spain, celebrates 25 years of cancer research, significantly improving survival rates for multiple myeloma and other cancers through advancements in treatments and a focus on understanding intercellular communication within tumors.
25 Years of Cancer Research at CIC: Extending Lives and Transforming Treatments
The Centro de Investigación del Cáncer (CIC) in Salamanca, Spain, celebrates 25 years of cancer research, significantly improving survival rates for multiple myeloma and other cancers through advancements in treatments and a focus on understanding intercellular communication within tumors.
Progress
48% Bias Score
Gut Microbiota: A Key Factor in Cancer Treatment Efficacy
Research shows the gut microbiota significantly impacts cancer treatment efficacy; balanced microbiota enhances immunotherapy and chemotherapy responses, while dysbiosis may cause resistance and promote tumor development; manipulating the microbiota through probiotics, prebiotics, or fecal transplan...
Gut Microbiota: A Key Factor in Cancer Treatment Efficacy
Research shows the gut microbiota significantly impacts cancer treatment efficacy; balanced microbiota enhances immunotherapy and chemotherapy responses, while dysbiosis may cause resistance and promote tumor development; manipulating the microbiota through probiotics, prebiotics, or fecal transplan...
Progress
44% Bias Score
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Progress
48% Bias Score
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Progress
44% Bias Score
New Broad-Spectrum Antivenom Shows Promise in Mice Trials
Researchers have developed a new broad-spectrum antivenom using antibodies from a volunteer who was repeatedly exposed to various snake venoms; this antivenom showed effectiveness against 19 of the world's deadliest snakes in mice trials, offering a potential solution to the high mortality rates cau...
New Broad-Spectrum Antivenom Shows Promise in Mice Trials
Researchers have developed a new broad-spectrum antivenom using antibodies from a volunteer who was repeatedly exposed to various snake venoms; this antivenom showed effectiveness against 19 of the world's deadliest snakes in mice trials, offering a potential solution to the high mortality rates cau...
Progress
36% Bias Score
Novel Antivenom Developed Using Antibodies from Man Who Self-Administered Snake Venom
Tim Friede's 18-year self-experimentation involving over 850 snake venom doses resulted in a novel, broadly protective antivenom created by scientists using his antibodies; this antivenom offers protection against 13 of 19 deadliest snake species and could revolutionize snakebite treatment globally.
Novel Antivenom Developed Using Antibodies from Man Who Self-Administered Snake Venom
Tim Friede's 18-year self-experimentation involving over 850 snake venom doses resulted in a novel, broadly protective antivenom created by scientists using his antibodies; this antivenom offers protection against 13 of 19 deadliest snake species and could revolutionize snakebite treatment globally.
Progress
40% Bias Score
Cytomegalovirus Infection Improves Melanoma Immunotherapy Response
An Oxford University study published in Nature Medicine reveals that prior cytomegalovirus infection significantly improves melanoma immunotherapy response in approximately 400 patients, leading to better outcomes and suggesting new avenues for treatment.
Cytomegalovirus Infection Improves Melanoma Immunotherapy Response
An Oxford University study published in Nature Medicine reveals that prior cytomegalovirus infection significantly improves melanoma immunotherapy response in approximately 400 patients, leading to better outcomes and suggesting new avenues for treatment.
Progress
36% Bias Score
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Progress
48% Bias Score
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Progress
44% Bias Score
Doctor's Melanoma Diagnosis Highlights Risks of Skin Lesions and Rare Complication
A Scottish doctor, Alastair Muir, 63, received a terminal melanoma diagnosis in 2023 after initially misidentifying a lesion on his heel. The cancer spread to his leg and pelvis, and he also developed vision-threatening melanoma-associated retinopathy. Despite a grim prognosis, he is undergoing immu...
Doctor's Melanoma Diagnosis Highlights Risks of Skin Lesions and Rare Complication
A Scottish doctor, Alastair Muir, 63, received a terminal melanoma diagnosis in 2023 after initially misidentifying a lesion on his heel. The cancer spread to his leg and pelvis, and he also developed vision-threatening melanoma-associated retinopathy. Despite a grim prognosis, he is undergoing immu...
Progress
52% Bias Score
Snakebite Antivenom Breakthrough from Self-Experimentation
An American herpetologist, Tim Friede, allowed himself to be bitten by hundreds of venomous snakes to build immunity; his blood yielded two antibodies neutralizing many snake venoms, potentially revolutionizing antivenom treatment, currently costing thousands of lives annually.
Snakebite Antivenom Breakthrough from Self-Experimentation
An American herpetologist, Tim Friede, allowed himself to be bitten by hundreds of venomous snakes to build immunity; his blood yielded two antibodies neutralizing many snake venoms, potentially revolutionizing antivenom treatment, currently costing thousands of lives annually.
Progress
36% Bias Score
NHS England to Offer Faster Injectable Cancer Immunotherapy to 15,000 Patients Annually
The NHS England will provide up to 15,000 cancer patients annually with injectable nivolumab, a faster, more efficient immunotherapy for 15 cancer types, saving significant treatment time and freeing up hospital resources, at no extra cost to the NHS.
NHS England to Offer Faster Injectable Cancer Immunotherapy to 15,000 Patients Annually
The NHS England will provide up to 15,000 cancer patients annually with injectable nivolumab, a faster, more efficient immunotherapy for 15 cancer types, saving significant treatment time and freeing up hospital resources, at no extra cost to the NHS.
Progress
40% Bias Score
Showing 25 to 36 of 79 results